Friday, March 20, 2015 2:42:59 PM
Through his Pope Enterprises private entity, Clifford Pope is one of the shares recipients in the scheme although he received shares in only the other five public companies (TWDL, ENTI, HALB, CWIR and GEAR). CEOs from some of the other companies are also share recipients.
It's a backwards plan in which the share recipients are supposed to sell the shares they receive and put 90% of the proceeds in escrow until their "commitment amount" is reached after which they are free to keep all of their proceeds. The premise also requires that the proceeds in escrow be given to the two farm operators who are supposed to then construct the farms and apply for licenses to cultivate and sell MMJ. IF they are successful in constructing the farms, obtaining licenses and eventually cultivating and selling MMJ, some of the profits are to be split with the six public companies who financed the construction through the issuance of billions of free-trading shares.
The "potential" profits that have been claimed in press releases are disclosed in the deal's Confidential Private Disclosure Memorandum as being purely "hypothetical" and used only for the purpose of "illustration."
In other words, there is definitely no income without first massively diluting this stock (as well as the other five) and even then there is no assurance that the proceeds obtained by the selling share recipients will eventually be used to construct profitable MMJ farms or that IJJP and the others will ever receive one dime in income.
It's dilution today for hypothetical income years down the road.
This has been previously documented with links and explained in multiple posts including the following:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111414743
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110947200
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111414743
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110947200
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM